Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Richard A Hubner

Showing results (81-90 of 106) with videos related to

Pageof 11
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 29, 2022
Expanding Therapeutic Opportunities for Extrapulmonary Neuroendocrine CarcinomaMelissa Frizziero, Elaine Kilgour, Kathryn L Simpson, et al.
Healthcare (Basel, Switzerland)|October 28, 2023
Prognosis Discussion and Referral to Community Palliative Care Services in Patients with Advanced Pancreatic Cancer Treated in a Tertiary Cancer CentreSarah Clelland, Christina L Nuttall, Helen E Stott, et al.
World Journal of Clinical Oncology|May 2, 2020
Prognostic importance of lymph node yield after curative resection of gastroenteropancreatic neuroendocrine tumoursJaseela Chiramel, Rose Almond, Astrid Slagter, et al.
Acta Oncologica (Stockholm, Sweden)|April 8, 2022
Markers of tumor inflammation as prognostic factors for overall survival in patients with advanced pancreatic cancer receiving first-line FOLFIRINOX chemotherapyKonstantinos Kamposioras, George Papaxoinis, Mohamed Dawood, et al.
Clinical and Experimental Medicine|January 21, 2026
Maintaining oxaliplatin therapy after hypersensitivity reactions: real-world experience with a desensitisation protocolEleftherios Christodoulis, Panagiotis J Vlachostergios, Jacqueline Connell, et al.
European Journal of Cancer (Oxford, England : 1990)|November 21, 2018
Quality of life in metastatic pancreatic cancer patients receiving liposomal irinotecan plus 5-fluorouracil and leucovorinRichard A Hubner, Antonio Cubillo, Jean-Frédéric Blanc, et al.
British Journal of Cancer|March 29, 2017
Quality-adjusted survival with combination nal-IRI+5-FU/LV vs 5-FU/LV alone in metastatic pancreatic cancer patients previously treated with gemcitabine-based therapy: a Q-TWiST analysisUwe Pelzer, Jean-Frédéric Blanc, Davide Melisi, et al.
World Journal of Gastroenterology|October 30, 2019
Retrospective study on mixed neuroendocrine non-neuroendocrine neoplasms from five European centresMelissa Frizziero, Xin Wang, Bipasha Chakrabarty, et al.
Liver International : Official Journal of the International Association for the Study of the Liver|May 24, 2016
A multicentre comparison between Child Pugh and Albumin-Bilirubin scores in patients treated with sorafenib for Hepatocellular CarcinomaJulien Edeline, Jean-Frédéric Blanc, Philip Johnson, et al.
Investigational New Drugs|February 12, 2017
Phase II study of the antibody-drug conjugate TAK-264 (MLN0264) in patients with metastatic or recurrent adenocarcinoma of the stomach or gastroesophageal junction expressing guanylyl cyclase CKhaldoun Almhanna, Maria Luisa Limon Miron, David Wright, et al.
Pageof 11

Showing results (81-90 of 106) with videos related to

Sort By:
Pageof 11
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 29, 2022
Expanding Therapeutic Opportunities for Extrapulmonary Neuroendocrine CarcinomaMelissa Frizziero, Elaine Kilgour, Kathryn L Simpson, et al.
Healthcare (Basel, Switzerland)|October 28, 2023
Prognosis Discussion and Referral to Community Palliative Care Services in Patients with Advanced Pancreatic Cancer Treated in a Tertiary Cancer CentreSarah Clelland, Christina L Nuttall, Helen E Stott, et al.
World Journal of Clinical Oncology|May 2, 2020
Prognostic importance of lymph node yield after curative resection of gastroenteropancreatic neuroendocrine tumoursJaseela Chiramel, Rose Almond, Astrid Slagter, et al.
Acta Oncologica (Stockholm, Sweden)|April 8, 2022
Markers of tumor inflammation as prognostic factors for overall survival in patients with advanced pancreatic cancer receiving first-line FOLFIRINOX chemotherapyKonstantinos Kamposioras, George Papaxoinis, Mohamed Dawood, et al.
Clinical and Experimental Medicine|January 21, 2026
Maintaining oxaliplatin therapy after hypersensitivity reactions: real-world experience with a desensitisation protocolEleftherios Christodoulis, Panagiotis J Vlachostergios, Jacqueline Connell, et al.
European Journal of Cancer (Oxford, England : 1990)|November 21, 2018
Quality of life in metastatic pancreatic cancer patients receiving liposomal irinotecan plus 5-fluorouracil and leucovorinRichard A Hubner, Antonio Cubillo, Jean-Frédéric Blanc, et al.
British Journal of Cancer|March 29, 2017
Quality-adjusted survival with combination nal-IRI+5-FU/LV vs 5-FU/LV alone in metastatic pancreatic cancer patients previously treated with gemcitabine-based therapy: a Q-TWiST analysisUwe Pelzer, Jean-Frédéric Blanc, Davide Melisi, et al.
World Journal of Gastroenterology|October 30, 2019
Retrospective study on mixed neuroendocrine non-neuroendocrine neoplasms from five European centresMelissa Frizziero, Xin Wang, Bipasha Chakrabarty, et al.
Liver International : Official Journal of the International Association for the Study of the Liver|May 24, 2016
A multicentre comparison between Child Pugh and Albumin-Bilirubin scores in patients treated with sorafenib for Hepatocellular CarcinomaJulien Edeline, Jean-Frédéric Blanc, Philip Johnson, et al.
Investigational New Drugs|February 12, 2017
Phase II study of the antibody-drug conjugate TAK-264 (MLN0264) in patients with metastatic or recurrent adenocarcinoma of the stomach or gastroesophageal junction expressing guanylyl cyclase CKhaldoun Almhanna, Maria Luisa Limon Miron, David Wright, et al.
Pageof 11